Anavex Life Sciences Corp. (NASDAQ:AVXL) traded down 6% on Monday . The stock traded as low as $3.60 and last traded at $3.61, with a volume of 860,322 shares changing hands. The stock had previously closed at $3.84.

Several equities research analysts have weighed in on the stock. Maxim Group reaffirmed a “buy” rating on shares of Anavex Life Sciences Corp. in a research note on Monday, June 6th. FBR & Co reaffirmed an “outperform” rating and issued a $10.00 price target on shares of Anavex Life Sciences Corp. in a research note on Tuesday, July 26th. Finally, Zacks Investment Research downgraded shares of Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th.

The firm’s market capitalization is $112.88 million. The company has a 50 day moving average of $5.63 and a 200-day moving average of $4.88.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last released its earnings results on Wednesday, May 11th. The company reported ($0.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.10. On average, analysts anticipate that Anavex Life Sciences Corp. will post ($0.34) EPS for the current year.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.